Aflibercept
A new study published in Frontiers in Medicine has found that faricimab, a bispecific monoclonal antibody, has significantly improved visual outcomes in patients with diabetic macular edema (DME) by concurrently inhibiting vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). This dual-targeting mechanism enhances vascular stability, reduces leakage, and enables
Aflibercept
DelveInsight's "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. The report covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products, and provides therapeutic assessment by product
Aflibercept
Research findings on the effectiveness of the biosimilar CT-P42 in treating diabetic macular edema have been discussed in a new report. A 24-week phase 3 analysis earlier demonstrated equivalent efficacy and comparable tolerability between CT-P42 and the reference aflibercept in participants with diabetic macular edema. The latest study reports long-term
Aflibercept
A new systematic review and meta-analysis published in the Graefe's Archive for Clinical and Experimental Ophthalmology has found that switching to faricimab after prior anti-vascular endothelial growth factor (VEGF) therapy can significantly improve symptoms of diabetic macular edema (DME). The study, conducted by researchers at Tabriz University of
Aflibercept
Research from Agostino Gemelli University Hospital in Rome, Italy, has shed light on the effects of a faricimab loading phase on diabetic macular edema. The study, which evaluated 46 eyes with resistant diabetic macular edema, found significant improvements in visual acuity and anatomic outcomes. The findings suggest that faricimab could
Aflibercept
Researchers at the University of Texas Medical Branch in Galveston, Texas, have published a new study on the treatment of macular edema, a common cause of vision loss in people with diabetes. The study, which was presented in the Middle East African Journal of Ophthalmology, found that a treatment protocol
Aflibercept
Researchers at F. Hoffmann-La Roche Ltd. have conducted clinical trials to evaluate the efficacy and safety of Faricimab, a novel bispecific antibody targeting VEGF-A and Ang-2, in treating diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The trials, YOSEMITE/RHINE and TENAYA/LUCERNE, compared Faricimab to aflibercept, a
